Cost of illness for bipolar disorder: a systematic review of the economic burden

@article{KleineBudde2014CostOI,
  title={Cost of illness for bipolar disorder: a systematic review of the economic burden},
  author={K. Kleine-Budde and Elina Touil and J. Moock and A. Bramesfeld and W. Kawohl and W. R{\"o}ssler},
  journal={Bipolar Disorders},
  year={2014},
  volume={16},
  pages={337 - 353}
}
Recent reviews lack important information on the high cost‐of‐illness worldwide for bipolar disorder (BD). Therefore, the present study systematically analyzed those costs, their driving components, and the methodological quality with which the few existing cost‐of‐illness investigations have been performed. 
Economic evaluations of non-pharmacological interventions and cost-of-illness studies in bipolar disorder: A systematic review.
TLDR
It is suggested that non-pharmacological intervention for BD might be cost-effective and the number of EEs was relatively low and methodology was heterogenous and therefore encourage future research to widen the body of knowledge in this research field. Expand
Clinical staging model in offspring of parents with bipolar disorder: a systematic review
TLDR
The utility of clinical stage modelling as a framework for identifying precursor disorders to later onset of bipolar disorder (BD) in OPBD and the utility of developmental psychopathology framework are established. Expand
The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review
TLDR
Improved clinical management of BD/BD-I and associated comorbidities, together with better medication adherence, may reduce health-care costs and improve patient outcomes. Expand
Global economic burden of schizophrenia: a systematic review
TLDR
The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients and results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease. Expand
Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis.
TLDR
The prevalence of unrecognized bipolar disorder was not significantly affected by study-level variations in the risk of bias and there was no evidence for publication bias. Expand
Clinical Risk Constellations for the Development of Bipolar Disorders
The early recognition of psychiatric disorders has been a focus of research in the last decades and has led to improvements in clinical care, especially in the area of early psychosis. LikeExpand
Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study
TLDR
Use of administrative databases has permitted retrieval of comprehensive information about therapeutic pathways, diagnostic history and costs in patients affected by schizophrenia or BD. Expand
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes
TLDR
It is suggested that asenapine is a cost-effective alternative to olanzapine in mixed episode BD-I patients, and may have specific advantages in this population, potentially leading to healthcare sector savings and improved outcomes. Expand
Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data
TLDR
Patients with bipolar I disorder treated with adjunctive oral AAPs treated with lurasidone had lower hospitalizations and fewer all-cause hospital days vs. olanzapine and quetiapine, and ziprasidone. Expand
Cognitive impairment and consumption of mental healthcare resources in outpatients with bipolar disorder.
TLDR
In euthymic outpatients with bipolar disorder, those with suspected cognitive impairment had consumed a higher number of health resources over the previous year, and these preliminary results may foster similar studies on the relationship between mental healthcare resource use and cognitive dysfunction in bipolar disorder and other psychiatric disorders. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands
TLDR
To assess the societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands, a large number of patients are diagnosed with the condition at a young age. Expand
[The costs of bipolar disorder].
TLDR
The optimization of mental health system resources should prompt incentives to better screen, diagnose, and treat patients with a bipolar disorder. Expand
A systematic review of the evidence of the burden of bipolar disorder in Europe
TLDR
Bipolar disorder is a major and underestimated health problem in Europe, and a number of issues impact on the economic burden of the disease, such as comorbidities, suicide, early death, unemployment or underemployment. Expand
Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review.
TLDR
The results indicate that the costs arising from EDs are substantial, and no COI provided a comprehensive estimate of costs, and the comparability of CEA was limited. Expand
Economic burden of rheumatoid arthritis: a systematic review.
TLDR
The economic impact of RA in terms of cost was reported to be substantial by all studies reviewed, however, methodological problems meant that discrepancies in the average (per person) annual cost of RA existed across studies. Expand
Cost-of-illness studies of depression: a systematic review.
TLDR
Depression is associated with a high economic burden and conducting COI-studies of depression along the line noted in the review could help provide the opportunity to expose differences in costs associated with different approaches to disease management. Expand
Annual cost of managing bipolar disorder to the UK healthcare system.
TLDR
The direct medical cost of managing bipolar disorder in the UK healthcare system is considerable and therapeutic strategies that optimize community-based management, prevention of recurrence and hospitalization could reduce the economic burden of this illness. Expand
Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis.
TLDR
The number and cost of both prescriptions and health care encounters suggest that bipolar disorder, especially bipolar I, is both difficult and costly to manage. Expand
Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population.
TLDR
Controlling treatment costs for BPD patients requires focusing on patients with key comorbidities and monitoring the association between treatment regimen and resource use. Expand
Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population
TLDR
It is suggested that patients with bipolar disorder who receive only mood stabilizer therapy incur lower bipolar-related and all-cause cost than those receiving only atypical antipsychotics. Expand
...
1
2
3
4
5
...